| Endocrine therapy plus zoledronic acid in premenopausal breast cancer M Gnant, B Mlineritsch, W Schippinger, G Luschin-Ebengreuth, ... New England Journal of Medicine 360 (7), 679-691, 2009 | 1279 | 2009 |
| Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials ED Saad, A Katz, M Buyse Journal of clinical oncology 28 (11), 1958-1962, 2010 | 203 | 2010 |
| Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature ED Saad, A Katz, PM Hoff, M Buyse Annals of oncology 21 (1), 7-12, 2010 | 165 | 2010 |
| Lung cancer in Brazil LH Araujo, C Baldotto, G Castro Jr, A Katz, CG Ferreira, C Mathias, ... Jornal Brasileiro de Pneumologia 44, 55-64, 2018 | 133 | 2018 |
| Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely defined ED Saad, A Katz Annals of oncology 20 (3), 460-464, 2009 | 132 | 2009 |
| Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine ED Saad, MC Machado, D Wajsbrot, R Abramoff, PM Hoff, J Tabacof, ... International journal of gastrointestinal cancer 32, 35-41, 2002 | 119 | 2002 |
| Primary systemic chemotherapy of invasive lobular carcinoma of the breast A Katz, ED Saad, P Porter, L Pusztai The lancet oncology 8 (1), 55-62, 2007 | 116 | 2007 |
| Global variation in postoperative mortality and complications after cancer surgery: a multicentre, prospective cohort study in 82 countries SR Knight, CA Shaw, R Pius, TM Drake, L Norman, AO Ademuyiwa, ... The Lancet 397 (10272), 387-397, 2021 | 114 | 2021 |
| Oncologia: bases clínicas do tratamento AM Murad, A Katz Oncologia: bases clínicas do tratamento, 435-435, 1996 | 106 | 1996 |
| Colon cancer vaccines: an update E Merika, MW Saif, A Katz, C Syrigos, M Morse In vivo 24 (5), 607-628, 2010 | 96 | 2010 |
| Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC FH Knebel, F Bettoni, AK Shimada, M Cruz, JV Alessi, MV Negrão, ... Lung Cancer 108, 238-241, 2017 | 69 | 2017 |
| Câncer de pulmão no Brasil LH Araujo, C Baldotto, G Castro Jr, A Katz, CG Ferreira, C Mathias, ... Jornal Brasileiro de Pneumologia 44, 55-64, 2018 | 67 | 2018 |
| The role of histone deacetylase inhibitors in metastatic breast cancer B Zucchetti, AK Shimada, A Katz, G Curigliano The Breast 43, 130-134, 2019 | 63 | 2019 |
| Management of anemia in cancer patients A Calabrich, A Katz Future oncology 7 (4), 507-517, 2011 | 60 | 2011 |
| Critérios comuns de toxicidade do Instituto Nacional de Câncer dos Estados Unidos ED Saad, PM Hoff, RP Carnelós, A Katz, YAS Novis, M Pietrocola, ... Revista Brasileira de cancerologia 48 (1), 63-96, 2002 | 43 | 2002 |
| A prospective randomized evaluation of three schedules of mesna administration in patients receiving an ifosfamide-containing chemotherapy regimen: sustained efficiency and … A Katz, S Epelman, A Anelli, EF Gorender, SM Cruz, RM Oliveira, ... Journal of cancer research and clinical oncology 121, 128-131, 1995 | 42 | 1995 |
| Multigene assays in early breast cancer: Insights from recent phase 3 studies C Markopoulos, DM Hyams, HL Gomez, M Harries, S Nakamura, T Traina, ... European journal of surgical oncology 46 (4), 656-666, 2020 | 35 | 2020 |
| Assessment of quality of life in advanced non-small-cell lung cancer: an overview of recent randomized trials ED Saad, K Adamowicz, A Katz, J Jassem Cancer treatment reviews 38 (6), 807-814, 2012 | 35 | 2012 |
| Assessment of quality of life in advanced breast cancer. An overview of randomized phase III trials K Adamowicz, J Jassem, A Katz, ED Saad Cancer treatment reviews 38 (5), 554-558, 2012 | 31 | 2012 |
| Quality-of-life benefits and evidence of antitumour activity for patients with brain metastases treated with gefitinib A Katz, P Zalewski British Journal of Cancer 89 (2), S15-S18, 2003 | 30 | 2003 |
